

COMPANY OVERVIEW

Propanc is currently focused on developing new cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancers. We have developed a formulation of anti-cancer compounds which exert a number of effects designed to control or prevent tumors from recurring and spreading throughout the body. Our products involve or employ proenzymes, which are inactive precursors of enzymes.

RECENT NEWS

Propanc Biopharma Targets \$3B+ Pancreatic Cancer Market with PRP: 85%+ Tumor Inhibition in Breakthrough Proenzyme Therapy

Mar 12 2026, 8:45 AM EDT

Propanc Biopharma Executes Service Agreement with FyoniBio to Establish & Validate Pharmacokinetics Assay for Phase 1b First-In-Human Study

Mar 10 2026, 8:45 AM EDT

Propanc Biopharma's Lead Asset PRP Shows >85% Tumor Growth Inhibition in Preclinical Pancreatic Models

Mar 3 2026, 8:45 AM EST

STOCK OVERVIEW

Symbol	PPCB	Propanc Biopharma, Inc. T: +61-03-9882-6723
Exchange	Nasdaq	irteam@propanc.com
Market Cap	2.46m	
Last Price	\$0.1178	
52-Week Range	\$0.1119 - \$11.00	

03/23/2026 08:00 PM EDT

INVESTOR RELATIONS

MANAGEMENT TEAM

James Nathanielsz
CEO and Executive Chairman

Prof. Dr. Klaus Kutz
Chief Medical Officer

Dr. Ralf Brandt
Research & Development Director

Jeannine Zimmerman
Chief Financial Officer

PROPANC BIOPHARMA, INC.

302/6 Butler Street
Camberwell, VIC 3124
AU

DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.